Article
Immunology
Monika D. Scuron, Brittany L. Fay, Andrew J. Connell, Michael T. Peel, Paul A. Smith
Summary: The study aimed to investigate the effectiveness of ruxolitinib cream in experimentally-induced dermatitis. Ruxolitinib cream showed strong anti-inflammatory and anti-itch effects by modulating the JAK-STAT pathway. The research provides strong evidence for the use of ruxolitinib cream as a potent therapeutic agent for the clinical management of atopic dermatitis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Antonio Lahera, Laura Vela-Martin, Pablo Fernandez-Navarro, Pilar Llamas, Jose L. Lopez-Lorenzo, Javier Cornago, Javier Santos, Jose Fernandez-Piqueras, Maria Villa-Morales
Summary: This study identified the JAK3(Q988P) mutation in a T-ALL patient, which plays an oncogenic role in leukemogenesis and confers resistance to conventional treatment as well as ruxolitinib. These findings highlight the importance of evaluating this mutation for guiding personalized therapeutic strategies.
MOLECULAR CARCINOGENESIS
(2023)
Article
Pediatrics
Yasir Bin Khathlan, Sajdi Almutairi, Fahad B. Albadr, Abdullah A. Alangari, Abdulrahman Alsultan
Summary: This case report describes a successful treatment using the JAK inhibitor ruxolitinib in an 8-year-old female with TREX1-related disorders. The patient achieved prolonged remission without adverse effects. Longer-term follow-up is needed to evaluate the efficacy and safety of ruxolitinib in this population.
FRONTIERS IN PEDIATRICS
(2023)
Article
Immunology
Carmen Mestre-Duran, Carla Martin-Cortazar, Blanca Garcia-Solis, Alicia Pernas, Lidia Pertinez, Victor Galan, Luisa Sisinni, Laura Clares-Villa, Alfonso Navarro-Zapata, Karima Al-Akioui, Adela Escudero, Cristina Ferreras, Antonio Perez-Martinez
Summary: Natural killer (NK) cells, as part of the innate immune system, play a vital role in defending against infected and transformed cells. The balance between inhibitory and activating receptors on NK cells controls their cytotoxic capability. The JAK/STAT pathway and Toll-like receptors (TLRs) are key factors in NK cell activation and response to pathogens. Ruxolitinib, a JAK1/2 inhibitor, has shown moderate effects on TLR pathway activation and cytokine production in NK cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Hong-Tai Tzeng, I-Tsu Chyuan, Jenn-Haung Lai
Summary: The JAK/STAT signaling pathway plays a crucial role in immune regulation, affecting cell proliferation, survival, inflammation, and immune tolerance. Aberrant activation of this pathway can lead to autoimmune diseases and cancer progression, while targeting JAK/STAT has shown efficacy in suppressing inflammation. The success of small-molecule JAK inhibitors in treating rheumatologic diseases highlights their therapeutic potential in other conditions.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Cell Biology
Zhan-Yang Qian, Ren-Yi Kong, Sheng Zhang, Bin-Yu Wang, Jie Chang, Jiang Cao, Chao-Qin Wu, Zi-Yan Huang, Ao Duan, Hai-Jun Li, Lei Yang, Xiao-Jian Cao
Summary: The study found that RUX can inhibit the inflammatory response after traumatic spinal cord injury by suppressing the interferon-gamma/JAK/STAT pathway, thereby reducing secondary injury and producing neuroprotective effects.
NEURAL REGENERATION RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Yue Song, Jingshi Wang, Yini Wang, Zhao Wang
Summary: Ruxolitinib proved to be effective and relatively safe in treating the inflammatory symptoms of active CAEBV in patients who had not responded to previous treatments. The medication led to favorable outcomes such as fever reduction, decreased liver enzyme levels, and improved cytopenia in some patients, with a median remission duration of 7.1 weeks for those who responded to the drug.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medical Laboratory Technology
Su-yun Wang, Xu-lei Xie, Jia-yi Liang, Zhi-yong Cheng
Summary: This study evaluated the expression of JAK2V617F mutation and the JAK/STAT pathway in MPN patients and HEL cells. The results showed significant differences in the expression of p-JAK2, SOCS-1, and SHP-1 between JAK2V617F positive MPN patients and controls. After treatment, the expressions of p-JAK2, SOCS-1, and SHP-1 also significantly changed. Ruxolitinib had a significant effect on HEL cell viability and apoptosis.
CLINICAL LABORATORY
(2023)
Article
Biochemistry & Molecular Biology
Yanpeng Li, Zhilei Li, Kutty Selva Nandakumar, Rikard Holmdahl
Summary: A recent study found that a single nucleotide variant (NCF1(R90H)) on the NCF1 gene was associated with low production of reactive oxygen species (ROS) and causative for several autoimmune diseases. The study induced psoriasis in the skin and psoriatic arthritis using mannan and evaluated the effects. It was found that the NCF1(90H) variant promoted psoriasis and psoriatic arthritis by hyperactivating macrophages, expanding keratinocytes, and increasing numbers of γδT17 cells.
Article
Biochemistry & Molecular Biology
Aida Bea, Juan Garcia Valero, Andrea Irazoki, Carlos Lana, Guillermo Lopez-Lluch, Manuel Portero-Otin, Patricia Perez-Galan, Javier Inserte, Marisol Ruiz-Meana, Antonio Zorzano, Marta Llovera, Daniel Sanchis
Summary: Research has shown that cardiac fibroblasts have higher endurance to ischemic conditions, expressing more BCL2 gene and participating in response to hypoxia, oxidative stress, respiration, and JAK/STAT signaling pathways. The survival advantage of CF in experimental ischemia is controlled by the JAK2/STAT signaling pathway.
Article
Chemistry, Multidisciplinary
Nazia Afroze, Sreepoorna Pramodh, Abdulmajeed G. Almutary, Tahir A. Rizvi, Naushad Rais, Ritu Raina, Md Faiyazuddin, Abdullah M. Alnuqaydan, Arif Hussain
Summary: This study reveals that Kaempferol can induce apoptosis, reduce cell viability, and exhibit antioxidant and anti-inflammatory effects on HeLa cells. It also inhibits excessive cell division. Therefore, Kaempferol has the potential to serve as a natural therapeutic agent.
APPLIED SCIENCES-BASEL
(2022)
Article
Chemistry, Medicinal
Magnus Nilsson, Magdalena Rhedin, Ramon Hendrickx, Susanne Berglund, Antonio Piras, Parmis Blomgran, Anders Cavallin, Mia Collins, Goran Dahl, Bilel Dekkak, Therese Ericsson, Niklas Hagberg, Ann Aurell Holmberg, Agnes Leffler, Anders J. Lundqvist, Thomais Markou, James Pinkerton, Lars Ronnblom, Stacey Siu, Vanessa Taylor, Tiiu Wennberg, Dimitrios Zervas, Arian D. J. Laurence, Suman Mitra, Maria G. Belvisi, Mark Birrell, Annika Borde
Summary: AZD0449 and AZD4604 show potential as inhibitors of signaling pathways involved in asthmatic immune responses, with target engagement demonstrated locally in the lung. These findings support the clinical development of AZD0449 and AZD4604 for the treatment of patients with asthma.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Immunology
Yigeng Cao, Jiali Wang, Shan Jiang, Mengnan Lyu, Fei Zhao, Jia Liu, Mingyang Wang, Xiaolei Pei, Weihua Zhai, Xiaoming Feng, Sizhou Feng, Mingzhe Han, Yuanfu Xu, Erlie Jiang
Summary: Ruxolitinib has been found to enhance the functions of PMN-MDSCs through JAK/STAT and ROS-MAPK/NF-kappa B signaling pathways, leading to improved treatment outcomes for SR-aGVHD. Monitoring the frequencies and functions of MDSCs can be used to evaluate responses to Ruxolitinib. Furthermore, Ruxolitinib prevents the differentiation of mature myeloid cells and promotes the accumulation of MDSCs by inhibiting STAT5.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2023)
Review
Chemistry, Medicinal
Maddalena Napolitano, Gabriella Fabbrocini, Angelo Ruggiero, Vincenzo Marino, Mariateresa Nocerino, Cataldo Patruno
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects children and adults, with dysfunction of the epidermal barrier and immune dysregulation playing key roles in its pathogenesis. Recent studies have highlighted the importance of Janus kinase (JAK) enzymes in AD, leading to the emergence of oral and topical JAK inhibitors as new treatment options. Abrocitinib, an oral JAK1 inhibitor, has shown promising results in reducing the severity of moderate-to-severe AD with minimal adverse events, comparable to established treatments like dupilumab.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Cell Biology
Bhawana Maurya, Satya Surabhi, Rituparna Das, Pranjali Pandey, Ashim Mukherjee, Mousumi Mutsuddi
Summary: Mahe, an RNA helicase, regulates Notch signaling and neuronal development in Drosophila. The study demonstrates that Mahe can promote apoptosis by modulating the JAK/STAT pathway components. Through transcriptome profiling and RNA immunoprecipitation experiments, the study reveals the regulatory mechanism of Mahe on the JAK/STAT pathway.
CELL DEATH & DISEASE
(2021)